Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:


Last Updated: December 6, 2021

DrugPatentWatch Database Preview

Patent: 6,042,822

➤ Subscribe for complete access

« Back to Dashboard

Summary for Patent: 6,042,822
Title: Interferon polymer conjugates
Abstract:Compositions containing alpha interferon conjugated to a substantially non-antigenic polymer are disclosed in which at least about 30% of the conjugates include covalent attachment of the alpha interferon to the substantially non-antigenic polymer at a histidine. Also disclosed is a process for preparing the conjugates. The process includes contacting an alpha interferon with a succinimidyl carbonate-activated substantially non-antigenic polymer at a pH which is sufficient to facilitate covalent attachment of the polymer on a histidine of the alpha interferon.
Inventor(s): Gilbert; Carl W. (Powder Springs, GA), Park-Cho; Myung-ok (Seoul, KR)
Assignee: Enzon, Inc. (Piscataway, NJ)
Application Number:09/287,476
Patent Claims:see list of patent claims

Details for Patent 6,042,822

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Merck Sharp & Dohme Corp. PEGINTRON peginterferon alfa-2b Injection 103949 2001-01-19 ⤷  Free Forever Trial 2013-11-10
Merck Sharp & Dohme Corp. SYLATRON peginterferon alfa-2b For Injection 103949 2011-03-29 ⤷  Free Forever Trial 2013-11-10
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

International Patent Family for US Patent 6,042,822

Country Patent Number Estimated Expiration
South Africa 9811590 ⤷  Free Forever Trial
South Africa 969557 ⤷  Free Forever Trial
World Intellectual Property Organization (WIPO) 9932139 ⤷  Free Forever Trial
World Intellectual Property Organization (WIPO) 9718832 ⤷  Free Forever Trial
World Intellectual Property Organization (WIPO) 9513090 ⤷  Free Forever Trial
United States of America 5951974 ⤷  Free Forever Trial
>Country >Patent Number >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.